VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
+0.42%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.9B
AUM Growth
+$499M
(+36%)
Cap. Flow
+$501M
Cap. Flow
% of AUM
26.36%
Top 10 Holdings %
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$127M |
| 2 |
Alcon
ALC
|
+$46.3M |
| 3 |
Revolution Medicines
RVMD
|
+$44.1M |
| 4 |
Amicus Therapeutics
FOLD
|
+$43.7M |
| 5 |
Exact Sciences
EXAS
|
+$37.2M |
Top Sells
| 1 |
Insmed
INSM
|
+$82M |
| 2 |
UroGen Pharma
URGN
|
+$23.8M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
| 4 |
Liquidia Corp
LQDA
|
+$18.1M |
| 5 |
Establishment Labs
ESTA
|
+$17.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Travere Therapeutics
TVTX
$1.93B
| $5.25M | 0.28% |
+355,000
| New | +$5.25M |
|
52
Enliven Therapeutics
ELVN
$1.19B
| $5.02M | 0.26% |
+250,000
| New | +$5.02M |
|
53
Voyager Therapeutics
VYGR
$236M
| $4.59M | 0.24% |
1,475,000
+225,582
| +18% | +$702K |
|
54
Zimmer Biomet
ZBH
$20.7B
| $4.56M | 0.24% |
+50,000
| New | +$4.56M |
|
55
Becton Dickinson
BDX
$54.9B
| $4.31M | 0.23% |
+25,000
| New | +$4.31M |
|
56
Ventyx Biosciences
VTYX
$170M
| $4.28M | 0.23% |
2,000,000
| – | – |
|
57
Lantheus
LNTH
$3.65B
| $4.09M | 0.22% |
+50,000
| New | +$4.09M |
|
58
Neurocrine Biosciences
NBIX
$14.3B
| $3.77M | 0.2% |
+30,000
| New | +$3.77M |
|
59
Applied Therapeutics
APLT
$63.4M
| $3.58M | 0.19% |
11,500,000
| – | – |
|
60
Fate Therapeutics
FATE
$111M
| $2.82M | 0.15% |
2,515,000
-850
| -0% | -$952 |
|
61
Passage Bio
PASG
$22.3M
| $2.44M | 0.13% |
305,000
| – | – |
|
62
Alto Neuroscience
ANRO
$105M
| $2.09M | 0.11% |
950,000
+35,000
| +4% | +$77K |
|
63
Sutro Biopharma
STRO
$82.3M
| $1.86M | 0.1% |
2,600,000
| – | – |
|
|
OKUR
64
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$34.8M
| $1.52M | 0.08% |
635,000
| – | – |
|
65
Viridian Therapeutics
VRDN
$1.62B
| $1.4M | 0.07% |
+100,000
| New | +$1.4M |
|
66
Alector
ALEC
$283M
| $1.37M | 0.07% |
976,992
+472,452
| +94% | +$661K |
|
67
enGene Holdings
ENGN
$278M
| $1.35M | 0.07% |
370,000
| – | – |
|
68
Arcutis Biotherapeutics
ARQT
$2.15B
| $1.33M | 0.07% |
+95,000
| New | +$1.33M |
|
69
Atara Biotherapeutics
ATRA
$85.5M
| $726K | 0.04% |
94,085
| – | – |
|
70
MacroGenics
MGNX
$111M
| $339K | 0.02% |
280,000
| – | – |
|
71
Tenax Therapeutics
TENX
$27.6M
| $308K | 0.02% |
53,439
| – | – |
|
72
Traws Pharma
TRAW
$13.2M
| $222K | 0.01% |
149,800
-25,200
| -14% | -$37.3K |
|
73
Arcturus Therapeutics
ARCT
$484M
| – | – |
-211,790
| Closed | -$2.24M |
|
|
CNTA
74
Centessa Pharmaceuticals
CNTA
$2.8B
| – | – |
-14,888
| Closed | -$214K |
|
|
75
Establishment Labs
ESTA
$1.11B
| – | – |
-433,193
| Closed | -$17.7M |
|